Pharmacist Impact on Use of Valproic Acid Therapy in Patients With Neurological Disorders
Study Details
Study Description
Brief Summary
Sodium valproate is a well-known anticonvulsant used in the treatment of epilepsy and bipolar disorder, as well as other psychiatric conditions requiring the administration of mood stabilizers. Aim of the present study is to assess sodium valproate usage among patients with neurological disorders.
Prescriptions of 600 patients from out-patient clinic of neurology department at Mansoura university teaching hospital were analyzed in a retrospective cohort study which conducted between January 2015 and December 2017. Data collected include: demographic data, medical history, drug-drug interaction, polypharmacy, medication error, doses and therapeutic duplication. A designed and structured form was used to collect the required information.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This retrospective cohort study was conducted at the outpatient's clinics of Neurology department at tertiary care hospital. After identifying problems with use and completing a follow-up, 3 months of educational intervention (Lectures) among professionals was given. As this study is observational informed consent from all subjects was waived. The subjects were enrolled on the basis of inclusion and exclusion criteria. Patients receiving at least 7 days of Valproic acid, between 10-70 years old, both sexes, were included in the study figure 1. 600 Prescriptions were reviewed between January of 2015 to December of 2017 for patients who were suffering from any psychotic illness and were on psychiatric medications. Then patient were educated and followed up for six months.
Inclusion/ exclusion criteria: The study population was limited to those who were continuously eligible for the outpatient during the entire study period. Patients were identified through pharmacy drug prescriptions By hospital policy all drugs are prescribed for a maximum period of 3 months. Consequently, all patients presented at least twice during the study period. A designed and structured form was used to collect the required information. Data then collected on Microsoft Excel sheet, which included patients' initial therapeutic indications, concomitant use of oral medications, significant adverse drug effects and any drug -drug interaction.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Phase 1 n=600 |
Other: Educational intervention
3 months of educational intervention (Lectures) among professionals was given.
Other Names:
|
| Phase 2 n=504 |
Other: Educational intervention
3 months of educational intervention (Lectures) among professionals was given.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Valproate dose (Number) [3 month]
Right dose
- Number of drugs (Number) [3 Months]
Number of drugs included in the prescriptions analyzed
- Medication errors (Number) [3 Months]
Medication errors regarding frequency or dose of Sodium valproate
- Adherence (Number) [3 Months]
Adherence to medication regimens
- Tolerability (Number) [3 Months]
tolerability was assessed through monitoring of ADRs and recorded in the patient's file.
Eligibility Criteria
Criteria
Inclusion Criteria:
- The study population was limited to those who prescribed with valproate and were continuously eligible for the outpatient during the entire study period. Patients were identified through pharmacy drug prescriptions By hospital policy all drugs are prescribed for a maximum period of 3 months. Consequently, all patients presented at least twice during the study period.
Exclusion Criteria:
- Patients who not use valproate.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Damanhour University
- Mansoura University
Investigators
- Principal Investigator: Rehab H Werida, Ass. Prof., Damanhour University
Study Documents (Full-Text)
None provided.More Information
Publications
- Bell JS, Whitehead P, Aslani P, McLachlan AJ, Chen TF. Drug-related problems in the community setting: pharmacists' findings and recommendations for people with mental illnesses. Clin Drug Investig. 2006;26(7):415-25. doi: 10.2165/00044011-200626070-00003.
- Thakkar KB, Jain MM, Billa G, Joshi A, Khobragade AA. A drug utilization study of psychotropic drugs prescribed in the psychiatry outpatient department of a tertiary care hospital. J Clin Diagn Res. 2013 Dec;7(12):2759-64. doi: 10.7860/JCDR/2013/6760.3885. Epub 2013 Dec 15.
- valproic acid therapy